CN117442608A - 化合物u1158在治疗红斑狼疮中的应用 - Google Patents
化合物u1158在治疗红斑狼疮中的应用 Download PDFInfo
- Publication number
- CN117442608A CN117442608A CN202311696443.4A CN202311696443A CN117442608A CN 117442608 A CN117442608 A CN 117442608A CN 202311696443 A CN202311696443 A CN 202311696443A CN 117442608 A CN117442608 A CN 117442608A
- Authority
- CN
- China
- Prior art keywords
- lupus erythematosus
- lupus
- content
- compound
- tnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010025135 lupus erythematosus Diseases 0.000 title claims abstract description 77
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 238000011282 treatment Methods 0.000 title claims description 15
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 16
- 208000005777 Lupus Nephritis Diseases 0.000 claims abstract description 14
- 102000003777 Interleukin-1 beta Human genes 0.000 claims abstract description 9
- 108090000193 Interleukin-1 beta Proteins 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 30
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 28
- 230000002757 inflammatory effect Effects 0.000 claims description 23
- 229940079593 drug Drugs 0.000 claims description 22
- -1 elixirs Substances 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 15
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 102000000589 Interleukin-1 Human genes 0.000 claims description 9
- 108010002352 Interleukin-1 Proteins 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 8
- 229960005069 calcium Drugs 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 206010057887 neonatal lupus erythematosus Diseases 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 206010067737 Lupus hepatitis Diseases 0.000 claims description 5
- 206010066391 Lupus myocarditis Diseases 0.000 claims description 5
- 206010063663 Neuropsychiatric lupus Diseases 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000003862 glucocorticoid Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- 239000003430 antimalarial agent Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 13
- 230000006872 improvement Effects 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 15
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 238000000465 moulding Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 206010040882 skin lesion Diseases 0.000 description 5
- 231100000444 skin lesion Toxicity 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 240000004922 Vigna radiata Species 0.000 description 2
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 2
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WEEYASWRWODDTJ-ZDUSSCGKSA-N (2s)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl]-2,3-dihydro-1,4-benzothiazine-7-carbonyl]amino]hexanedioic acid Chemical compound C1CSC2=CC(C(=O)N[C@@H](CCCC(O)=O)C(O)=O)=CC=C2N1CC1=NC2=C(N)N=C(N)N=C2N=C1 WEEYASWRWODDTJ-ZDUSSCGKSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- RONWGALEIBILOG-VCSAERELSA-N (s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 RONWGALEIBILOG-VCSAERELSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010019263 Heart block congenital Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002583 anti-histone Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 210000003293 antilymphocyte serum Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- OGODKNYCTJYXFF-UHFFFAOYSA-N bis(4-methylbenzoyl) 2,3-dihydroxybutanedioate Chemical compound C1=CC(C)=CC=C1C(=O)OC(=O)C(O)C(O)C(=O)OC(=O)C1=CC=C(C)C=C1 OGODKNYCTJYXFF-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 201000004395 congenital heart block Diseases 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229940008228 intravenous immunoglobulins Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229910000275 saponite Inorganic materials 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了化合物U1158在治疗红斑狼疮中的应用。本发明提供的化合物U1158对红斑狼疮有一定的改善作用,降低血清IL‑1β及TNF‑α效果明显,在降低血清anti‑dsDNA及anti‑nRNP IgG的同时,能够改善Scr和BUN,提示U1158的抗炎药效强,对狼疮性肾炎具有治疗作用。
Description
技术领域
本发明属于生物医药领域,具体涉及化合物在治疗红斑狼疮中的应用。
背景技术
红斑狼疮(LE)是一种典型的自身免疫性结缔组织病,多见于15~40岁女性。导致狼疮的异常自身免疫的确切原因是未知的。遗传基因、病毒、紫外光和药品可能都起到一些作用。遗传因素、雌性激素和环境因素的相互作用下,会导致患者体内的T淋巴细胞数量减少、B细胞过度增生和自身产生大量抗体等情况,也会和其体内的自身抗原进行结合,形成免疫复合物,这些免疫复合物会沉积在患者的小血管、关节、皮肤和肾小球等部位,在补体细胞的参与之下则会导致患者出现组织坏死和急慢性炎症等症状,最终会导致患者出现淋巴细胞减少症、溶血性贫血和身体多个系统损害等症状,对患者的身体健康伤害非常巨大。
而目前虽然有多种针对红斑狼疮的治疗药物,但大多都收效甚微。因此,本领域亟需寻找新的治疗红斑狼疮的药物。
发明内容
为弥补现有技术的不足,本发明提供了化合物U1158在治疗红斑狼疮中的应用。
为实现上述目的,本发明采用如下技术方案:
本发明的第一方面提供了化合物U1158或其药学上可接受的盐在制备缓解红斑狼疮的症状和/或治疗红斑狼疮的药物中的应用,化合物U1158的结构式如式(Ⅰ)所示:
。
进一步,所述缓解红斑狼疮的症状和/或治疗红斑狼疮包括(1)-(4)中的至少一种:
(1)降低炎症因子的水平;
(2)降低anti-dsDNA IgG含量;
(3)降低Scr含量;
(4)降低BUN含量。
进一步,所述炎症因子包括IL-1β、TNF-α、IL-26、IL-22、IL-20、IL-10、IL-38、IL-33、IL-18中的一种或几种。
进一步,所述炎症因子选自IL-1β和/或TNF-α。
进一步,所述药物还包括其他治疗红斑狼疮的药物。
进一步,所述其他治疗红斑狼疮的药物包括糖皮质激素、非甾体类抗炎药、抗疟药、免疫抑制剂、钙剂和维生素D中的一种或几种。
进一步,所述红斑狼疮包括盘状红斑狼疮、亚急性皮肤型红斑狼疮、深在性红斑狼疮、新生儿红斑狼疮、药物性红斑狼疮、系统性红斑狼疮。
进一步,所述红斑狼疮选自系统性红斑狼疮。
进一步,所述系统性红斑狼疮包括狼疮性肾炎、神经精神性狼疮、狼疮性肺炎、狼疮性心肌炎或狼疮性肝炎。
进一步,所述系统性红斑狼疮选自狼疮性肾炎。
本发明的第二方面提供了一种缓解红斑狼疮的症状和/或治疗红斑狼疮的药物,所述药物包括化合物U1158或其药学上可接受的盐。
进一步,所述药物还包括药用辅料。
进一步,所述药用辅料包括稀释剂、粘合剂、表面活性剂、致湿剂、吸附载体、润滑剂、填充剂、崩解剂中的一种或多种。
进一步,所述药物的剂型包括颗粒、粉末、片剂、胶囊、糖浆、栓剂、注射剂、乳液、酏剂、悬浮液或溶液。
进一步,所述红斑狼疮包括盘状红斑狼疮、亚急性皮肤型红斑狼疮、深在性红斑狼疮、新生儿红斑狼疮、药物性红斑狼疮、系统性红斑狼疮。
进一步,所述红斑狼疮选自系统性红斑狼疮。
进一步,所述系统性红斑狼疮包括狼疮性肾炎、神经精神性狼疮、狼疮性肺炎、狼疮性心肌炎或狼疮性肝炎。
进一步,所述系统性红斑狼疮选自狼疮性肾炎。
本发明的第三方面提供了化合物U1158或其药学上可接受的盐在制备调控如下任一种或几种物质的产品中的应用:
(1)炎症因子的水平;
(2)anti-dsDNA IgG含量;
(3)Scr含量;
(4)BUN含量。
进一步,所述炎症因子包括IL-1β、TNF-α、IL-26、IL-22、IL-20、IL-10、IL-38、IL-33、IL-18中的一种或几种。
进一步,所述炎症因子选自IL-1β和/或TNF-α。
本发明的第四方面提供了一种调节如下任一种或几种物质的方法,所述方法包括施用化合物U1158或其药学上可接受的盐,所述物质包括:
(1)炎症因子的水平;
(2)anti-dsDNA IgG含量;
(3)Scr含量;
(4)BUN含量。
进一步,所述炎症因子包括IL-1β、TNF-α、IL-26、IL-22、IL-20、IL-10、IL-38、IL-33、IL-18中的一种或几种。
进一步,所述炎症因子选自IL-1β和/或TNF-α。
进一步,所述方法为非治疗目的的方法。
本发明的优点和有益效果:
本发明提供的化合物U1158对红斑狼疮有一定的改善作用,降低血清IL-1β及TNF-α效果明显,在降低血清anti-dsDNA及anti-nRNP IgG的同时,能够改善Scr和BUN,提示U1158的抗炎药效强,对狼疮性肾炎具有治疗作用。
附图说明
图1是红斑狼疮小鼠造模及给药试验流程图;
图2是U1158改善红斑狼疮导致的肾脏病理损伤以及免疫复合物IgG在肾小球上的沉积图。
具体实施方式
下文提供了本说明书中使用的一些术语的定义。除非另有说明,本文中使用的所有技术和科学用语通常具有和本发明所属领域的普通技术人员通常理解的意思相同的意思。
本发明提供了化合物U1158或其药学上可接受的盐在制备缓解红斑狼疮的症状和/或治疗红斑狼疮的药物中的应用。
作为本发明的一种实施方式,药学上可接受的盐是指任何酸加成盐或碱加成盐,其抗衡离子在所述盐的药用剂量下对于患者是无毒的。药学上可接受的盐的主体是本领域中已熟知的。如果在这些组合物中使用本申请的化合物的药学上可接受的盐,则那些盐优选地衍生自无机酸或有机酸和碱。在此类酸式盐中包括但不限于以下各项:乙酸盐、己二酸盐、海藻酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐、硫酸氢盐、丁酸盐、柠檬酸盐、樟脑酸盐、樟脑磺酸盐、环戊烷丙酸盐、二葡糖酸盐、十二烷基硫酸盐、乙磺酸盐、富马酸盐、lucoheptanoate、甘油磷酸盐、半硫酸盐、庚酸盐、己酸盐、盐酸盐、氢溴酸盐、氢碘酸盐、2-羟基乙磺酸盐、乳酸盐、马来酸盐、甲磺酸盐、2-萘磺酸盐、烟酸盐、草酸盐、扑酸盐、果胶酸盐、过硫酸盐、3-苯基-丙酸盐、苦味酸盐、特戊酸盐、丙酸盐、琥珀酸盐、酒石酸盐、硫氰酸盐、甲苯磺酸盐、十一酸盐、氢卤化物(例如,盐酸盐和氢溴酸盐)、硫酸盐、磷酸盐、硝酸盐、氨基磺酸盐、丙二酸盐类、水杨酸盐、亚甲基-双-b-羟萘甲酸盐、龙胆酸盐、羟乙基磺酸盐、二-对-甲苯酰基酒石酸盐、乙烷磺酸盐、环己基氨基磺酸盐、奎尼酸盐等。药学上可接受的碱加成盐包括但不限于衍生自碱金属或碱土金属碱或常规有机碱的那些,诸如三乙胺、吡啶、哌啶、吗啉、N-甲基吗啉、铵盐、碱金属盐(诸如钠盐和钾盐)、碱土金属盐(诸如钙盐和镁盐)、具有有机碱的盐(诸如二环己基胺盐、N-甲基-D-葡糖胺)、以及具有氨基酸诸如精氨酸、赖氨酸的盐。
作为本发明的一种实施方式,红斑狼疮包括盘状红斑狼疮(DLE)、亚急性皮肤型红斑狼疮(SCLE)、深在性红斑狼疮(LEP)、新生儿红斑狼疮(NLE)、药物性红斑狼疮(DIL)、系统性红斑狼疮(SLE)等亚型。
其中,盘状红斑狼疮,主要侵犯皮肤,是红斑狼疮中最轻的类型。少数可有轻度内脏损害,少数病例可转变为系统性红斑狼疮。皮肤损害初起时为一片或数片鲜红色斑,绿豆至黄豆大,表面有粘着性鳞屑,以后逐渐扩大,呈圆形或不规则形,边缘色素明显加深,略高于中心。损害主要分布于日光照射部位,如面部、耳轮及头皮,少数可累及上胸、手背、前臂、口唇及口腔黏膜也可受累。多数患者皮损无自觉症状,但很难完全消退。新损害可逐渐增多或多年不变。盘状皮损在日光暴晒或劳累后加重。头皮上的损害可引起永久性脱发。陈旧性损害偶尔可发展成皮肤鳞状细胞癌。
亚急性皮肤型红斑狼疮,临床上较少见,是一种特殊的中间类型。皮肤损害有两种,一种是环状红斑型,另一个类型是丘疹鳞屑型。两种皮损多数病例单独存在,少数可同时存在。皮损常反复发作,绝大多数患者均有内脏损害,但严重者很少,主要症状为关节痛、肌肉痛、反复低热,少数有肾炎、血液系统改变。
深在性红斑狼疮又称狼疮性脂膜炎,同样是中间类型的红斑狼疮。皮肤损害为结节或斑块,位于真皮深层或皮下脂肪组织,其大小、数目不定,表面肤色正常或淡红色,质地坚实,无移动性。损害可发生于任何部位,最常见于颊部、臀部、臂部,其次为小腿和胸部。深在性红斑狼疮性质不稳定,可单独存在,以后即可转化为盘状红斑狼疮,也可转化为系统性红斑狼疮,或与它们同时存在。
新生儿红斑狼疮,表现为皮肤环形红斑和先天性心脏传导阻滞,有自陷性,一般在生后4~6个月内自行消退,心脏病变常持续存在。
药物性红斑狼疮主要表现为发热、关节痛、肌肉痛、面部蝶形红斑、口腔溃疡,可有浆膜炎。ANA、抗组蛋白抗体、抗ss-DNA抗体等可为阳性。停药后逐渐好转,病情较重者可给予适量糖皮质激素。
系统性红斑狼疮(systemic lupus erythematosus,SLE),是一种较常见的累及多器官系统的自身免疫性疾病,临床表现多种多样,病情呈反复发作与缓解交替过程。血清中出现以抗核抗体为代表的多种自身抗体和多系统累及是SLE的两个主要临床特征。几乎各种自身免疫性疾病的临床表现均有可能发生在SLE。因此,许多学者称之为自身免疫性疾病的原型。
在本发明的优选的实施方式中,红斑狼疮选自系统性红斑狼疮。
所述系统性红斑狼疮包括狼疮性肾炎、神经精神性狼疮、狼疮性肺炎、狼疮性心肌炎或狼疮性肝炎。
在本发明的具体实施方式中,所述系统性红斑狼疮选自狼疮性肾炎。
所述药物还包括其他治疗红斑狼疮的药物。
所述其他治疗红斑狼疮的药物包括但不限于糖皮质激素、非甾体类抗炎药、抗疟药、免疫抑制剂、钙剂和维生素D中的一种或几种。
其中,糖皮质激素包括但不限于氢化可的松、泼尼松、泼尼松龙、地塞米松、甲泼尼龙、曲安奈德、倍他米松。
非甾体类抗炎药包括但不限于阿司匹林、吲哚美辛、萘普生、萘普酮、双氯芬酸、布洛芬、尼美舒利、罗非昔布、塞来昔布。
抗疟药包括但不限于奎宁、氯喹、青蒿素、羟氯喹。
免疫抑制剂包括但不限于环磷酰胺、甲氨蝶呤、来氟米特、硫唑嘌呤、吗替麦考酚酯、MX-68、二盐酸阿替莫德、BMS-188667、CKD-461、利美索龙(rimexolone)、环孢素(cyclosporine)、他克莫司(tacrolimus)、胍立莫司(gusperimus)、抗淋巴细胞血清、冷冻干燥的磺酸化正常免疫球蛋白、红细胞生成素、集落刺激因子、白细胞介素、干扰素、静脉内免疫球蛋白、抗胸腺细胞球蛋白、RSLV-13。
钙剂和维生素D包括但不限于维生素D2、维生素D3、阿尔法骨化醇以及骨化三醇、葡萄糖酸钙、磷酸钙、乳酸钙、柠檬酸钙、乳钙、氨基酸钙。
除以上提到的药物外的其它药物包括例如抗细菌剂、抗真菌剂、抗原虫剂、抗生素、止咳和化痰药、镇静剂、麻醉剂、抗溃疡药、抗心律不齐剂、降压利尿药、抗凝血剂、镇定剂、安定药、抗肿瘤药、降血脂药、肌肉松弛剂、抗惊厥药、抗抑郁剂、抗过敏药、强心剂、心律不齐治疗药物、血管扩张剂、血管收缩剂、降压利尿剂、糖尿病治疗药、抗麻醉药、平喘药、尿频/尿失禁治疗药、特应性皮炎治疗剂、过敏性鼻炎治疗剂、增压剂、内毒素拮抗剂或内毒素抗体、信号转导抑制剂、炎性介体活性的抑制剂也可以与本申请的药物共同施用。
本发明提供了一种缓解红斑狼疮的症状和/或治疗红斑狼疮的药物,所述药物包括化合物U1158或其药学上可接受的盐。
所述药物还包括药用辅料。
作为本发明的一种实施方式,药用辅料用于指这样一种材料,该材料与接受对象,优选哺乳动物,更优选人相容,并且适于将活性剂递送到目标部位,同时不会终止该药剂的活性。与该药用辅料相关的毒性或副作用(如果存在)优选与用于活性剂预定用途的合理风险/效益比相称。
药用辅料包括但不限于稀释剂、粘合剂、表面活性剂、致湿剂、吸附载体、润滑剂、填充剂、崩解剂。这些药用辅料根据需要用于帮助配方的稳定性或有助于提高活性或它的生物有效性或在口服的情况下产生可接受的口感或气味,在这种药物中可以使用的制剂可以是其原始化合物本身的形式或任选地使用其药物学可接受的盐的形式,如此配制的药物根据需要可选择本领域技术人员已知的任何适当的方式把药物进行给药。
其中,稀释剂包括但不限于乳糖、氯化钠、葡萄糖、尿素、淀粉、水。
粘合剂包括但不限于淀粉、预胶化淀粉、糊精、麦芽糖糊精、蔗糖、阿拉伯胶、明胶、甲基纤维素、羧甲基纤维素、乙基纤维素、聚乙烯醇、聚乙二醇、聚乙烯比咯烷酮、海藻酸及海藻酸盐、黄原胶、羟丙基纤维素和羟丙基甲基纤维素。
表面活性剂包括但不限于聚氧化乙烯山梨聚糖脂肪酸酯、十二烷基硫酸钠、硬脂酸单甘油酯、十六烷醇。
致湿剂包括但不限于甘油。
吸附载体包括但不限于斑脱土、硅胶、高岭土和皂粘土。
润滑剂包括但不限于硬脂酸锌、单硬脂酸甘油酯、聚乙二醇、滑石粉、硬脂酸钙和镁、聚乙二醇、硼酸粉末、氢化植物油、硬脂富马酸钠、聚氧乙烯单硬脂酸酯、单月桂蔗糖酸酯、月桂醇硫酸钠、月桂醇硫酸镁、十二烷基硫酸镁。
填充剂包括但不限于甘露醇(粒状或粉状)、木糖醇、山梨醇、麦芽糖、赤藓糖、微晶纤维素、聚合糖、偶合糖、葡萄糖、乳糖、蔗糖、糊精、淀粉、海藻酸钠、海带多糖粉末、琼脂粉末、碳酸钙和碳酸氢钠。
崩解剂包括但不限于交联乙烯吡咯烷酮、羧甲基淀粉钠、低取代羟丙基甲基、交联羧甲基纤维素钠、大豆多糖。
作为本发明的一种实施方式,药物可以通过不同路径施用,包括静脉内、腹膜内、皮下、肌内、口服、经粘膜、直肠、透皮或吸入。在一些实施方案中,本申请的药物可通过口服施用来施用。对于口服施用,例如,药物可以被配制成常规口服剂型诸如胶囊、片剂和液体制剂诸如糖浆、酏剂和浓缩的滴剂。
作为本发明的一种实施方式,药物可以通过本领域众所周知的方法,如常规制粒、混合、溶解、囊封、冻干或乳化法等制造。该药物可以被制成各种形式,包括颗粒、沉淀物或微粒、粉末(包括冻干的粉末、旋转干燥的粉末或喷雾干燥的粉末、无定形粉末)、片剂、胶囊、糖浆、栓剂、注射剂、乳液、酏剂、悬浮液或溶液。
作为本发明的一种实施方式,药物被配制用于向哺乳动物,优选人施用药物。此类本申请的药物可以经口、肠胃外、通过吸入喷雾、表面、直肠、经鼻、经颊、阴道或经由植入的储集器施用。如本申请所使用,肠胃外包括皮下、静脉内、肌肉内、关节内、滑膜内、胸骨内、鞘内、肝内、病灶内及颅内注射或输注技术。优选地,所述药物是经口、静脉内或皮下施用。该药物可以被设计成短效、快速释放或长效的。又另外,该药物可以通过局部而非全身方式施用。
供口服的液体剂型包括但不限于,药学上可接受的乳液、微乳液、溶液、悬浮液、糖浆及酏剂。除本申请的化合物外,液体剂型可以含有本领域中常用的惰性稀释剂,如水或其它溶剂;增溶剂和乳化剂,如乙醇、异丙醇、碳酸乙酯、乙酸乙酯、苯甲醇、苯甲酸苄酯、丙二醇、1,3-丁二醇、环糊精、二甲基甲酰胺、油(尤其棉籽油、花生油、玉米油、胚芽油、橄榄油、蓖麻油及芝麻油)、甘油、四氢糠醇、聚乙二醇和脱水山梨糖醇的脂肪酸酯,以及其混合物。除惰性稀释剂外,口服组合物还可以包括佐剂,如润湿剂、乳化剂和悬浮剂、甜味剂、调味剂及芳香剂。
可以根据已知技术,使用适合的分散剂或润湿剂及悬浮剂来配制可注射制剂,例如无菌可注射水性或油性悬浮液。无菌可注射制剂也可以是于无毒肠胃外可接受的稀释剂或溶剂中的无菌可注射溶液、悬浮液或乳液,例如于1,3-丁二醇中的溶液。可以采用的可接受的媒剂和溶剂有水、林格氏溶液、U.S.P.及等渗氯化钠溶液。此外,通常采用无菌不挥发性油作为溶剂或悬浮介质。出于此目的,可以采用任何温和的不挥发性油,包括合成单酸甘油酯或二酸甘油酯。此外,在可注射制剂中使用了脂肪酸,如油酸。可以例如通过滤过细菌截留过滤器,或通过并在使用前加入可溶解于无菌水或其它无菌可注射介质中的无菌固体组合物形式的灭菌剂来对可注射配制物进行灭菌。配制用于肠胃外施用的药物可以通过快速注射或通过定时推注进行注射,或者可以通过连续输注施用。
供口服的固体剂型包括胶囊、片剂、粉剂及颗粒剂。在这些固体剂型中,将本申请的化合物与至少一种惰性、药用辅料,如柠檬酸钠或磷酸氢二钙,和/或以下各物混合:a)填充剂或增量剂,如淀粉、乳糖、蔗糖、葡萄糖、甘露糖醇及硅酸;b)粘合剂,如羧甲基纤维素、海藻酸酯、明胶、聚乙烯吡咯烷酮、蔗糖及阿拉伯胶;c)保湿剂,如甘油;d)崩解剂,如琼脂、碳酸钙、马铃薯或木薯淀粉、海藻酸、某些硅酸盐及碳酸钠;e)溶解延迟剂,如石蜡;f)吸收促进剂,如季铵化合物;g)润湿剂,如鲸蜡醇和单硬脂酸甘油酯;h)吸附剂,如高岭土和膨润土;及i)润滑剂,如滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、月桂基、硫酸钠,及其混合物。在胶囊、片剂及丸剂的情况下,所述剂型还可以包含缓冲剂,如磷酸盐或碳酸盐。
还可以使用如乳糖或奶糖以及高分子量聚乙二醇等作为赋形剂,将类似类型的固体组合物用作软和硬填充明胶胶囊中的填充剂。固体剂型片剂、糖衣丸、胶囊、丸剂及颗粒剂,可以用包衣和外壳制备,如肠溶包衣和本领域中众所周知的其它包衣。其可以任选地含有遮光剂并且还可以是使其在肠道某一部分中任选地以延缓的方式只释放活性成分或优先释放活性成分的组合物。可以使用的包埋组合物的实例包括聚合物质和蜡。还可以使用如乳糖或奶糖以及高分子量聚乙二醇等作为赋形剂,将类似类型的固体组合物用作软和硬填充明胶胶囊中的填充剂。
作为本发明的一种实施方式,施用是指将一定剂量/有效量的药物或化合物或药物组合物给予受试者(例如患者)的方法。施用可以是通过任何合适的手段,包括胃肠外,肺内和鼻内,及若期望用于局部治疗的话,损伤内施用。胃肠外输注包括例如肌肉内,静脉内,动脉内,腹膜内或皮下施用。部分根据施用是短暂的还是长期的,给药可以通过任何合适的路径,例如通过注射,诸如静脉内或皮下注射进行。本申请中涵盖各种给药日程表,包括但不限于单次施用或在多个时间点里的多次施用,推注施用和脉冲输注。
所述受试者,是指任何动物,还指人类和非人类的动物。非人类的动物包括所有脊椎动物,例如,哺乳动物,如非人灵长类动物(特别是高等灵长类动物)、绵羊、狗、啮齿类动物(如小鼠或大鼠)、豚鼠、山羊、猪、猫、兔、牛、和任何家畜或宠物;以及非哺乳动物,如鸡,两栖类,爬行动物等。
所述化合物U1158或其药学上可接受的盐在施用时,若受试者为小鼠时,可以施用的治疗有效剂量的化合物U1158或其药学上可接受的盐的剂量可以是0.1mg/kg、可以是0.3mg/kg、可以是0.5mg/kg、可以是0.7mg/kg、可以是1mg/kg、可以是1.2mg/kg、可以是1.3mg/kg、可以是1.5mg/kg、可以是1.7mg/kg、可以是1.9mg/kg、可以是2mg/kg、可以是2.1mg/kg、可以是2.3mg/kg、可以是2.4mg/kg、可以是3mg/kg、可以是3.5mg/kg、可以是4mg/kg、可以是6mg/kg、可以是7mg/kg、可以是8mg/kg、可以是10mg/kg,以及上述任意两点之间的剂量。
在本发明的优选的实施方式中,U1158或其药学上可接受的盐的施用剂量可以是0.1mg/kg、可以是0.3mg/kg、可以是0.5mg/kg、可以是0.7mg/kg、可以是1mg/kg、可以是1.2mg/kg、可以是1.3mg/kg、可以是1.5mg/kg、可以是1.7mg/kg、可以是1.9mg/kg、可以是2mg/kg、可以是2.1mg/kg、可以是2.3mg/kg、可以是2.4mg/kg,以及上述任意两点之间的剂量。
在本发明的具体实施方式中,所述化合物U1158或其药学上可接受的盐的施用剂量为2.4mg/kg。
若受试者为人时,可以施用的治疗有效剂量的化合物U1158或其药学上可接受的盐。精确的剂量将取决于治疗的目的并且将由本领域技术人员使用已知技术来确定。例如,用于缓解红斑狼疮的症状和/或治疗红斑狼疮的化合物U1158或其药学上可接受的盐可以是0.1mg/天、大于或等于0.5mg/天、大于或等于1mg/天、大于或等于2mg/天、大于或等于5mg/天、大于或等于10mg/天、大于或等于15mg/天、大于或等于20mg/天的剂量施用。可替代地,用于缓解红斑狼疮的症状和/或治疗红斑狼疮的化合物U1158或其药学上可接受的盐可以以约5mg/天、约7mg/天、约10mg/天、约12mg/天、约12.5mg/天、约13mg/天、约14mg/天、约14.5mg/天、约15mg/天、约15.5mg/天、约16mg/天、约16.6mg/天、约16.7mg/天或约17mg/天的剂量施用。
作为本发明的一种实施方式,有效量意思指这样一种量,当适当地施用给患者时,该量足以(a)使所治疗的病症或疾病状态的严重程度可检测的减轻;(b)改善或缓解患者疾病或病症的症状;或(c)减慢或防止所治疗的病症或疾病状态的发展,或以其它方式使所治疗的病症或疾病状态稳定或延长其稳定状态。还应了解,用于任何特定患者的具体剂量和治疗方案将取决于多种因素,包括所用特定化合物的活性;患者的年龄、体重一般健康状况、性别及饮食;施用时间;排泄速率;药物组合;治疗医师的判断;以及所治疗的特定疾病的严重程度。
本发明提供了一种调节如下任一种或几种物质的方法,所述方法包括施用化合物U1158或其药学上可接受的盐,所述物质包括:
(1)降低炎症因子的水平;
(2)降低anti-dsDNAIgG含量;
(3)降低Scr含量;
(4)降低BUN含量。
其中,所述炎症因子包括但不限于IL-1β、TNF-α、IL-26、IL-22、IL-20、IL-10、IL-38、IL-33、IL-18中的一种或几种。
在本发明的具体实施方案中,所述炎症因子选自IL-1β和/或TNF-α。
作为本发明的一种实施方式,调节或调控可互换使用,具体是指降低炎症因子的水平,降低anti-dsDNA IgG含量,降低Scr含量,降低BUN含量。
下面结合具体实施例进一步阐述此发明。应理解的是,在此描述的特定实施方式通过举例的方式来表示,并不作为对本发明的限制。在不偏离本发明范围的情况下,本发明的主要特征可以用于各种实施方式。
实施例
一、试验目的:
评估化合物U1158(舒尼替尼)干预对红斑狼疮模型小鼠病症的改善作用。根据小鼠血清IL-1β,TNF-α,血清anti-dsDNA抗体,抗核糖核蛋白(anti-nRNP),血清肌酐(Scr)及血尿素氮(BUN)这些指标来评价其治疗效果。
二、试验方法
1试验动物及耗材试剂
(1)40只雌性小鼠无菌C57 BL/6J,购自斯贝福(北京)生物技术有限公司,16-18g,6-7周。适应性饲养7天后,用降植烷造模,观察给药后小鼠免疫指标改善情况。
(2)降植烷(Pristane),购自Sigma Aldrich,模型组及药物组小鼠单次腹膜内注射0.5ml降植烷;正常对照组小鼠注射同等计量磷酸盐缓冲液(PBS),半小时内完成腹腔注射造模。4个月后完成红斑狼疮造模。
(3)小鼠血清IL-1β,TNF-αELISA试剂盒购自武汉博士德生物。血清肌酐(Scr)及血尿素氮(BUN)检测试剂盒购自北京索莱宝生物,光吸收法检测。血清抗双链DNA抗体IgG(anti-dsDNA IgG)购自武汉华美生物,抗核核糖核蛋白(anti-nRNP IgG)ELISA试剂盒购自Alpha Diagnostics。
2分组、造模及给药流程
(1)分组:试验共分为4组,每组8只小鼠。第一组为正常组,不造模,仅腹腔注射同等剂量的柠檬酸盐缓冲液,同时每天灌胃U1158溶剂(0.5%的羧甲基纤维素钠,CMC-Na);第二组为模型组,造模后,同时每天灌胃U1158溶剂(0.5%的羧甲基纤维素钠,CMC-Na);第三及第四组为治疗组,造模后每天灌胃U1158,剂量为2.5mg/kg及5mg/kg,治疗周期为120天。
(2)造模及给药步骤:造模组腹腔注射一次降植烷,剂量为0.5ml。造模第二天开始口腔灌胃给药U1158,每天一次,给药剂量分别为2.5mg/kg与5mg/kg。U1158都混悬于0.5%CMC-Na溶液中。总共给药时间为120天,每周称量一次动物体重,于造模后的第1周,第2、4个月检测上述血清指标。造模及给药试验流程如图1所示。
三、试验结果
各组小鼠体重变化(g,mean±SD)如表1所示。
表1各组小鼠体重变化
###,P<0.001,相比于正常组;*p<0.05,**p<0.01,***p<0.001,相比于模型组。
各组小鼠血清IL-1β水平(pg/ml,mean±SD)如表2所示。
表2各组小鼠血清IL-1β水平
###,P<0.001,同正常组相比;*,P<0.05;**,P<0.01;***,P<0.001同模型组相比。
各组小鼠血清TNF-α(pg/ml,mean±SD)如表3所示。
表3各组小鼠血清TNF-α水平
#,P<0.05;##,P<0.01;###,P<0.001,同正常组相比。***,P<0.001同模型组相比。
血清anti-dsDNA IgG的含量(ng/ml,mean±SD)如表4所示。
表4血清anti-dsDNA IgG的含量测定
##,P<0.01;###,P<0.001,同正常组相比。*,P<0.05;***,P<0.001同模型组相比。
血清anti-nRNP IgG含量(μg/ml,mean±SD)如表5所示。
表5血清anti-nRNP IgG含量
#,P<0.05;##,P<0.01;###,P<0.001,同正常组相比。**,P<0.01同模型组相比。
血清Scr含量(μmmol/l,mean±SD)如表6所示。
表6血清Scr含量
#,P<0.05;###,P<0.001,同正常组相比。*,P<0.05;**,P<0.01同模型组相比。
血清BUN含量(mmmol/l,mean±SD)如表7所示。
表7血清BUN含量
#,P<0.05;###,P<0.001,同正常组相比。*,P<0.05;**,P<0.01;***,P<0.001同模型组相比。
造模及治疗过程如图1所示,以上实验结果表明,降植烷造模后,小鼠体重显著下降,IL-1β和TNF-α水平显著升高,血清anti-dsDNA IgG的含量、anti-nRNP IgG含量、Scr含量及BUN含量显著升高,说明成功构建了狼疮性肾炎小鼠模型。
U1158对降植烷诱导的红斑狼疮有一定的改善作用,降低血清IL-1β及TNF-α效果明显,在降低血清anti-dsDNA及anti-nRNP IgG的同时,能够改善Scr和BUN,提示U1158的抗炎药效强,对免疫反应引起的肾损伤(狼疮性肾炎)具有一定的保护作用(表1-表7)。
而且,U1158显著改善了红斑狼疮导致的肾脏病理损伤以及免疫复合物IgG在肾小球上的沉积(图2)。
上述实施例的说明只是用于理解本发明的方法及其核心思想。应当指出,对于本领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以对本发明进行若干改进和修饰,这些改进和修饰也将落入本发明权利要求的保护范围内。
Claims (10)
1.化合物U1158或其药学上可接受的盐在制备缓解红斑狼疮的症状和/或治疗红斑狼疮的药物中的应用,化合物U1158的结构式如式(Ⅰ)所示:
2.根据权利要求1所述的应用,其特征在于,所述缓解红斑狼疮的症状和/或治疗红斑狼疮包括(1)-(4)中的至少一种:
(1)降低炎症因子的水平;
(2)降低anti-dsDNAIgG含量;
(3)降低Scr含量;
(4)降低BUN含量。
3.根据权利要求2所述的应用,其特征在于,所述炎症因子包括IL-1β、TNF-α、IL-26、IL-22、IL-20、IL-10、IL-38、IL-33、IL-18中的一种或几种;
优选地,所述炎症因子选自IL-1β和/或TNF-α。
4.根据权利要求1所述的应用,其特征在于,所述药物还包括其他治疗红斑狼疮的药物;
优选地,所述其他治疗红斑狼疮的药物包括糖皮质激素、非甾体类抗炎药、抗疟药、免疫抑制剂、钙剂和维生素D中的一种或几种。
5.根据权利要求1所述的应用,其特征在于,所述红斑狼疮包括盘状红斑狼疮、亚急性皮肤型红斑狼疮、深在性红斑狼疮、新生儿红斑狼疮、药物性红斑狼疮、系统性红斑狼疮;
优选地,所述红斑狼疮选自系统性红斑狼疮;
优选地,所述系统性红斑狼疮包括狼疮性肾炎、神经精神性狼疮、狼疮性肺炎、狼疮性心肌炎或狼疮性肝炎;
优选地,所述系统性红斑狼疮选自狼疮性肾炎。
6.一种缓解红斑狼疮的症状和/或治疗红斑狼疮的药物,其特征在于,所述药物包括化合物U1158或其药学上可接受的盐。
7.根据权利要求6所述的药物,其特征在于,所述药物还包括药用辅料;
优选地,所述药用辅料包括稀释剂、粘合剂、表面活性剂、致湿剂、吸附载体、润滑剂、填充剂、崩解剂中的一种或多种。
8.根据权利要求6所述的药物,其特征在于,所述药物的剂型包括颗粒、粉末、片剂、胶囊、糖浆、栓剂、注射剂、乳液、酏剂、悬浮液或溶液;
优选地,所述红斑狼疮包括盘状红斑狼疮、亚急性皮肤型红斑狼疮、深在性红斑狼疮、新生儿红斑狼疮、药物性红斑狼疮、系统性红斑狼疮;
优选地,所述红斑狼疮选自系统性红斑狼疮;
优选地,所述系统性红斑狼疮包括狼疮性肾炎、神经精神性狼疮、狼疮性肺炎、狼疮性心肌炎或狼疮性肝炎;
优选地,所述系统性红斑狼疮选自狼疮性肾炎。
9.化合物U1158或其药学上可接受的盐在制备调控如下任一种或几种物质的产品中的应用:
(1)炎症因子的水平;
(2)anti-dsDNA IgG含量;
(3)Scr含量;
(4)BUN含量;
优选地,所述炎症因子包括IL-1β、TNF-α、IL-26、IL-22、IL-20、IL-10、IL-38、IL-33、IL-18中的一种或几种;
优选地,所述炎症因子选自IL-1β和/或TNF-α。
10.一种调节如下任一种或几种物质的方法,其特征在于,所述方法包括施用化合物U1158或其药学上可接受的盐,所述物质包括:
(1)炎症因子的水平;
(2)anti-dsDNA IgG含量;
(3)Scr含量;
(4)BUN含量;
优选地,所述炎症因子包括IL-1β、TNF-α、IL-26、IL-22、IL-20、IL-10、IL-38、IL-33、IL-18中的一种或几种;
优选地,所述炎症因子选自IL-1β和/或TNF-α。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311696443.4A CN117442608A (zh) | 2023-12-12 | 2023-12-12 | 化合物u1158在治疗红斑狼疮中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311696443.4A CN117442608A (zh) | 2023-12-12 | 2023-12-12 | 化合物u1158在治疗红斑狼疮中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117442608A true CN117442608A (zh) | 2024-01-26 |
Family
ID=89583928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311696443.4A Pending CN117442608A (zh) | 2023-12-12 | 2023-12-12 | 化合物u1158在治疗红斑狼疮中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117442608A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023076404A1 (en) * | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
CN116712430A (zh) * | 2023-07-11 | 2023-09-08 | 厚安生物科技(济南)有限公司 | 舒尼替尼在治疗疾病中的应用 |
-
2023
- 2023-12-12 CN CN202311696443.4A patent/CN117442608A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023076404A1 (en) * | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
CN116712430A (zh) * | 2023-07-11 | 2023-09-08 | 厚安生物科技(济南)有限公司 | 舒尼替尼在治疗疾病中的应用 |
Non-Patent Citations (1)
Title |
---|
刘洪杰等: "特瑞普利联合舒尼替尼对晚期肾透明细胞癌VEGF、GDF-15及肾功能影响", 深圳中西医结合杂志, vol. 33, no. 17, 15 September 2023 (2023-09-15), pages 18 - 20 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015147240A1 (ja) | 敗血症の予防治療剤 | |
JPWO2004082715A1 (ja) | 炎症性腸疾患治療剤としての併用医薬 | |
US11045469B2 (en) | Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies | |
JP2011514379A (ja) | 選択的s1p1レセプターアゴニストの投与法 | |
WO2019156137A1 (ja) | 乾癬の治療薬 | |
CN113747899B (zh) | 用于治疗乙型肝炎的Toll样受体激动剂 | |
JP2016029116A (ja) | 炎症性腸疾患および/または過敏性腸管症候群に対する処置としてのphy906の使用 | |
CA3034875C (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
CN111419800B (zh) | 用于治疗红斑狼疮的药物制剂及其制备方法 | |
CN115484953A (zh) | 治疗细胞因子风暴综合症及相关疾病的方法 | |
JP2011500853A5 (zh) | ||
CN114929225A (zh) | 用于治疗类风湿性关节炎的喹啉衍生物 | |
CN117442608A (zh) | 化合物u1158在治疗红斑狼疮中的应用 | |
JPH11515020A (ja) | 自己免疫性疾患の処置用薬剤組成物 | |
JPH1053520A (ja) | 抗疲労剤 | |
WO2022253034A1 (zh) | 吡咯并嘧啶类化合物的用途 | |
JPH0359044B2 (zh) | ||
JP2008255008A (ja) | 滑膜細胞増殖抑制剤 | |
JP2021512140A (ja) | 肝細胞癌の治療のための併用療法 | |
CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
WO2023245470A1 (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 | |
US20230029336A1 (en) | Combination Therapy for Treating a Hematological Malignancy | |
JP2007326824A (ja) | 滑膜細胞増殖抑制剤、並びにこれを利用した薬用組成物及び治療方法 | |
JP2010111581A (ja) | ドーパミンd2様受容体アゴニストを有効成分とする医薬及びスクリーニング方法 | |
WO2018192469A1 (en) | Inhibitors of fabp4 and methods of treating arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |